Now I have all the information I need. Let me compose the final consolidated review, carefully verifying each claim against the paper.

---

## Summary

The paper proposes a three-component framework for the cold-start problem in biomedical image classification: (1) SSL pretraining (SimCLR) to obtain a meaningful latent representation, (2) furthest-point sampling (FPS) on the latent space to select the initial annotation budget, and (3) model soups to handle the absence of a validation set. The framework is evaluated on four diverse biomedical datasets and compared against random sampling and a reimplemented Cold PAWS baseline.

## Strengths

- **FPS on SSL latent representations outperforms random sampling and Cold PAWS on 3 of 4 biomedical datasets (Matek, ISIC, Retinopathy), with consistent advantage across a range of k values (Figure 4).** Table 1 shows FPS achieves the highest F1-macro on the majority of datasets, and Figure 4 confirms this advantage is robust to the choice of cluster count. This directly supports the claim that the framework delivers practical gains for biomedical cold-start scenarios.

- **The framework explicitly addresses a real-world constraint overlooked by prior cold-start work: the absence of a validation set.** The paper uses model soups (weight averaging over learning rates) as a principled alternative to validation-based selection, and Figure 6 demonstrates that this technique consistently improves classifier performance. The paper correctly notes (Section 3) that prior work has not specifically addressed the no-validation-set scenario in cold-start settings.

- **Evaluation spans four diverse, imbalanced biomedical datasets covering different imaging modalities (microscopy, dermoscopy, fundus photography, flow cytometry) and uses multiple metrics (F1-macro, balanced accuracy, Cohen's kappa, PR-AUC).** This breadth of evaluation on biomedical data is a genuine strength that goes beyond the natural-image focus of prior cold-start work.

- **FPS is shown to be substantially more computationally efficient than Cold PAWS (approximately 5× faster), with a favorable O(n·m) vs. O(n²·m) complexity.** Table 3 confirms this empirically, making the method practical for large biomedical datasets.

- **Ablation studies on SSL methods (SimCLR vs. SwAV vs. DINO) and sampling strategies are reasonably thorough**, identifying SimCLR as the best SSL backbone for this setting (Figure 5) and showing FPS's advantage across k values (Figure 4).

## Weaknesses

### Fatal
None.

### Major

- **Internally contradictory claim about the literature gap.** The paper states (line 30): "So far, none of the previous studies have applied their methods to the biomedical domain, where the cold start problem is both a practical concern and of significant importance." However, the paper itself cites Shetab Boushehri et al. (2022) for work on "biomedical images" (line 20) and Chandra et al. (2021) for demonstrating SSL effectiveness "in biomedical data" (line 74). The paper's own references contradict its claim that no prior cold-start study has addressed the biomedical domain. This mischaracterization of the gap weakens the novelty narrative and should be corrected.

### Minor

- **Baseline comparisons are limited given the claims about prior work.** The paper compares only to random sampling and a reimplemented Cold PAWS. It identifies Cold PAWS as SOTA (line 106) and does compare to it, but it also asserts (lines 28, 60) that methods by Chandra et al. (2021), Jin et al. (2022), and Yi et al. (2022) "haven't substantially outperformed random selection" — a claim that is stated without experimental evidence on the paper's own datasets. Including even one of these methods (or a simple k-means + closest-to-centroid baseline contextualized as a literature proxy) would strengthen the empirical support for this assertion. (Note: the paper does explain that Wang et al. (2022) cannot be compared due to code unavailability, which is a valid justification for that specific method.)

- **On the Jurkat dataset, FPS is not the best performer: closest/farthest (k=50) achieves higher F1-macro.** The paper honestly reports this, but it undermines the generality of FPS as the core sampling contribution. The claim in the abstract that "our strategy outperforms the state-of-the-art in all datasets" relies on the framework as a whole, but FPS specifically is not universally best.

### Trivial

- **The abstract's "7% improvement" claim is ambiguous.** The paper states: "achieves a 7% improvement on leukemia blood cell classification task." From context this appears to be the absolute F1-macro improvement of FPS over Cold PAWS on Matek (0.64 vs. 0.57 = 0.07), but the abstract does not specify whether this is absolute or relative improvement, nor over which baseline. Clarifying this would improve precision.

## Nice-to-Haves

- **Compare model soups against the alternative of using the held-out validation set (currently used only for SSL monitoring) for classifier hyperparameter selection.** The paper argues that with only 100 labels, a training-validation split is unreliable — this is reasonable — but an ablation showing that model soups match or exceed validation-based selection would further substantiate the claimed benefit. Currently, Figure 6 shows model soups improve over single-learning-rate classifiers, but the natural counterfactual (validation-based tuning) is absent.

- **Report statistical significance tests (e.g., paired bootstrapped confidence intervals) for the main comparisons.** The paper reports means and SDs from 5 runs, which is standard, but for borderline results (e.g., Jurkat comparisons with overlapping error bars), significance tests would help the reader assess reliability.

- **Include results for the larger annotation budgets (200, 500) mentioned in the paper.** The paper notes that experiments with budgets of 200 and 500 were conducted (line 133), but only the 100-budget results are reported. Showing whether the FPS advantage persists, diminishes, or grows with larger budgets would be informative.

## Removed Points

- **"No statistical significance testing" as a full weakness** — moved to Nice-to-Have. Reporting means and SDs from 5 runs is standard practice in this field; significance testing is an enhancement, not a requirement.
- **"Model soups not compared to validation-based selection" as a core weakness** — moved to Nice-to-Have. The paper's justification (unreliable validation with 100 labels) is reasonable and within its stated scope.
- **"The paper uses a 9:1 split so a validation set exists"** — the reviewer conflates the validation split used for SSL pretraining monitoring with a validation set for classifier head selection. The paper is clear about these being different uses.
- **"Cold PAWS reimplementation may differ from original"** — the paper explains the modifications (removing semi-supervised learning and test-set early stopping) as deliberate choices to ensure a fair comparison. This is a methodological strength, not a weakness.
- **"Missing experiments on annotation budget size"** — moved to Nice-to-Have. The paper mentions these experiments were conducted but only reports budget=100; reporting them would be additive, not a core flaw.
- **Strength Finder strength about "consistently outperforming"** — the language is slightly stronger than the evidence (FPS is not best on Jurkat), but the general claim of outperforming random and Cold PAWS on the majority of datasets is supported. The strength is kept with this caveat noted in the weakness section.

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface a perspective that the paper itself misses or that recontextualizes its contributions in a surprising way.

## Suggestions

1. **Correct the internally contradictory claim about prior work in the biomedical domain.** Either remove or qualify the statement that "none of the previous studies have applied their methods to the biomedical domain" (line 30), since the paper's own citations contradict it. A more accurate framing would acknowledge prior biomedical cold-start work while clarifying what distinguishes the current paper (e.g., the no-validation-set scenario, the specific combination of FPS + model soups, or the breadth of evaluation across four varied datasets).

2. **Add at least one additional baseline that represents prior cold-start methodology** — even a k-means + closest-to-centroid heuristic contextualized as a proxy for Chandra et al.'s or Jin et al.'s approach would substantially strengthen the empirical section and support the claim that prior methods "haven't substantially outperformed random."

3. **Clarify the "7% improvement" figure** by specifying the baseline, metric, and whether the number is absolute or relative.

4. **Consider reporting the budget=200 and budget=500 results** to show how the FPS advantage scales with annotation budget.

## Score and Decision

The paper addresses a practical problem with a clean pipeline and presents reasonably thorough experiments on diverse biomedical datasets. The main weaknesses are: (1) a factual error in characterizing the literature gap, (2) limited baseline comparisons given the claims made about prior work, and (3) the Jurkat exception showing FPS is not universally optimal. These issues are addressable but prevent the paper from fully establishing its claimed contribution in its current form. I recommend rejection with the expectation that the authors can address these issues substantially.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>